Michael Caplan, MD | Jubao Duan, PhD | Pablo Gejman, MD | Peter Hulick, MD | Karen Kaul, MD, PhD | Janardan Khandekar, MD | William Knaus, MD | Kathy Mangold, PhD | Alan Sanders, MD
Michael Caplan, MD; Chairman, Department of Pediatrics; Chief Scientific Officer, Research Institute
Dr. Caplan is Chairman of the Department of Pediatrics at NorthShore and Clinical Professor of Pediatrics at the University of Chicago, Pritzker School of Medicine. He is also the Chief Scientific Officer, Research Institute, NorthShore University HealthSystem. A graduate of the University of Illinois, and the University of Chicago with honors from the Pritzker School of Medicine, he completed his residency and neonatal-perinatal fellowship at Northwestern University Medical School and Ann & Robert H. Lurie Children’s Hospital of Chicago. Dr. Caplan joined the faculty of NorthShore in 1989 in the Division of Neonatology and Department of Pediatrics where he has served for the last 23 years.
Dr. Caplan is an internationally acclaimed physician-scientist in the area of neonatal necrotizing enterocolitis (NEC), a gastrointestinal disorder that affects 10% of newborns born weighing less than 3.5 pounds. He has published extensively on this subject, and has received multiple grants from the National Institutes of Health and the March of Dimes for his work investigating the causes and potential cures of this devastating disease. He lectures frequently on this subject, and he is currently working to test the potential effect of probiotics for the prevention of NEC.
Dr. Caplan has served as Program Chair for the Neonatal Network of the National Institutes of Child Health and Disease, a government-sponsored group of 16 neonatal intensive care units developing state-of-the-art clinical research to improve the lives of premature neonates. In addition, Dr. Caplan served as a member of an NIH study section that reviews grant proposals designed to investigate the causes and potential treatments of intestinal diseases such as Crohn’s disease.
Jubao Duan, PhD; Genomics Lab Director for Genomic Health Initiative (GHI). Director of the Unit of Functional Genomics in Psychiatry, Center for Psychiatric Genetics
Dr. Duan is in charge of generating the genomics data for the Genomic Health Initiative. Dr. Duan completed his PhD training in Molecular Genetics at the Beijing Institute of Basic Medical Sciences (China). Dr. Duan has extensive training in molecular genetics, molecular biology and complex disorder genomics.
He has successfully established a research program for transformation of human somatic tissues/cells into induced pluripotent stem cells (iPSCs), and differentiation of iPSCs into neurons. Dr. Duan was recently awarded R21MH102685 for which he will carry out genome editing at MIR137 (a genome-wide significantly associated schizophrenia microRNA locus) to create isogenic iPSC-derived neurons that differ only at the putatively functional variant sites, and then characterize the functional effects of the risk alleles on neuronal morphology, electrophysiology and transcription of downstream molecular targets.
Dr. Duan’s pioneering manuscript (~600 citations) demonstrated functional effects of DRD2 (dopamine receptor D2) variants on mRNA stability and receptor synthesis (PMID: 12554675). He has also made important contributions to several landmark papers published in leading journals on the molecular genetics of schizophrenia including recent genome-wide association studies. Dr. Duan has also participated in multiple other ‘omics studies (mRNA decay, transcriptome, and methylome), thus bringing substantial “systems biology” expertise to GHI.
Pablo Gejman, MD; Vice President for Genomic Research; Director, Genomic Health Initiative
Dr. Gejman is the Sauer Chair of Research at NorthShore. He received his MD from the University of Buenos Aires, trained in psychiatry at Hadassah University Hospital (Jerusalem), and completed research training in neuropsychiatric genetics as a Fellow of the John E. Fogarty International Center for Advanced Study in the Health Sciences at NIH.
Dr. Gejman’s work was instrumental for the detection of disease mutations for two genetic endocrine disorders: Albright's hereditary osteodystrophy and McCune-Albright syndrome. Dr. Gejman is a prolific, internationally renowned researcher with a focus on neuropsychiatric disorders. He has directed some of the largest international mega-collaborations and has held multiple multimillion-dollar NIH grants, with uninterrupted extramural federal funding. Prior to his current academic appointment, Dr. Gejman was Professor of Psychiatry at the University of Chicago (1998-2003) and tenured Professor of Psychiatry at Northwestern University (2003-2009). Dr. Gejman’s leadership and research work at NorthShore has led to significant progress in unraveling the genetics architecture of schizophrenia. He directed the collection of over 4,600 psychiatric and medical controls (and a similar number of schizophrenia cases). Wide scientific sharing of these clinical data and biospecimens has resulted in numerous studies of common medical genetic disorders and traits, in addition to multiple neuropsychiatric disorders.
Dr. Gejman oversees genomic research at NorthShore and also directs the Genomic Health Initiative.
Peter Hulick, MD, Division Head, Center for Medical Genetics
Peter J. Hulick is the Division Head and a medical geneticist at the NorthShore University HealthSystem Center for Medical Genetics and a Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine.
Dr. Hulick completed his clinical medical genetics residency at Harvard Medical School where his clinical concentrations included connective tissue diseases such as Marfan syndrome and Ehlers-Danlos syndrome while also maintaining a general genetics clinic.
His research during his Harvard genetics training consisted of identifying potential biomarkers of kidney cancer through gene expression profiling of tumor cell lines and the development of a clinical assay to detect kidney cancer at an early stage. He also studied the biological function of the folliculin gene product which, when mutated, causes the kidney cancer predisposition syndrome Birt-Hogg-Dube. During his medical genetics residency, he graduated with a masters in medical science degree from the Harvard Medical Scholars in Clinical Science program which trains individuals for careers in clinical research.
Dr. Hulick received his undergraduate degree in biology from Northwestern University in Evanston, IL and his medical degree from Jefferson Medical College, in Philadelphia, PA. He completed an internal medicine residency at Mayo Clinic, Jacksonville, FL before pursuing his clinical medical genetics training in Boston. Dr. Hulick is board certified in Internal Medicine and Clinical Genetics.
His clinical interests, in addition to general genetic syndromes, include connective tissue disease, cardiovascular, and kidney cancer genetics.
Karen Kaul, MD, PHD; Chair, Department of Pathology and Laboratory Medicine
Dr. Karen Kaul is Chair, Department of Pathology and Laboratory Medicine at NorthShore University HealthSystem, Clinical Professor of Pathology at the University of Chicago Pritzker School of Medicine, and holds the Duckworth family Chair at NorthShore for her work in molecular pathology. Dr. Kaul is board-certified in Anatomic Pathology, and also Molecular Genetic Pathology, and has devoted her career to development of the field of molecular pathology.
Dr. Kaul established one of the first clinical laboratories to perform DNA-based diagnostic testing in 1987, and established the Division of Molecular Diagnostics at NorthShore. Dr. Kaul's lab has been involved in the development of many in-house and commercial assays for rapid detection of pathogens and drug resistance microbial species, cancer biomarkers, tumor cells and more.
She is a past president of the Association for Molecular Pathology, and served as Editor in Chief of the Journal of Molecular Diagnostics until 2010. She has been significantly involved in molecular diagnostics efforts, education, regulation, and standardization of the practice of molecular pathology for several professional societies. She is the recipient of the 2008 Association for Molecular Pathology Leadership Award. In 2011, she was appointed as a Trustee of the American Board of Pathology. She was an ELAM (Executive Leadership in Academic Medicine) fellow in 2011-2012. In October 2012, she was named Chair of the Department of Pathology and Laboratory Medicine at NorthShore.
Janardan Dinkar Khandekar, MD, Director of the Center for Molecular Medicine
Dr. Janardan Khandekar is the Director of the Center for Molecular Medicine, and also a Clinical Professor at the University of Chicago Pritzker School of Medicine. He holds board of directors/J Khandekar Chair in Molecular Medicine. In addition, he is the Chairman of the Medical Advisory Committee for the NorthShore Kellogg Cancer Center.
Board-certified in Internal Medicine and Medical Oncology, Dr. Khandekar obtained his MBBS, MD from the University of Indore, India. His notable postgraduate career includes a Medical council of Canada Fellowship at the University of Montreal; a Fellowship in Oncology at Tufts University Hospitals; sabbaticals in Molecular Biology and Molecular Genetics at both Northwestern University and Baylor; and visiting Fellowship at the Weitzman Institute in Israel.
Dr. Khandekar was the founding Head of the Division of Medical Oncology, appointed Director of the Kellogg Cancer Centers and Kellogg/Scanlon endowed chair, serving in those roles for over 25 years. He also served as Chairman of the Department of Medicine at NorthShore and Professor of Medicine. During his tenure, the department had an unprecedented growth in terms of establishing new divisions, programs, recruitment of faculty and researchers. He also trained over 500 residents during this period and trained 10 physicians from India in oncology through a fellowship established in his father’s memory and is a mentor to foreign physicians through American Society of Oncology. He has authored /coauthored 116 full length peer reviewed papers and over 60 other publications.
William Knaus, MD, Director of Applied Genomics Research in Informatics; Director of Health Heritage Family Medical History Project
Dr. Knaus is an internationally recognized physician scientist, a member of the U.S. National Academy of Sciences, Institute of Medicine, and an active Emeritus Professor of the University of Virginia. In 2012 Dr. Knaus became Director of Applied Genomics Research in Informatics within NorthShore’s Center for Biomedical Informatics. Dr. Knaus came to NorthShore to bring Health Heritage to NorthShore's patients empowering them with the ability to electronically access and share their personal medical histories with family members. When combined with additional patient entered information and merged with new biologic and genomic data, Health Heritage can be one foundation for providing more precise, patient-centric genomic medicine.
Dr. Knaus was formerly Co-Director of the Intensive Care Unit at the George Washington University Hospital. There he developed a severity of illness and prognostic scoring system for critically ill hospitalized patients, named APACHE that has become the gold standard for describing acutely ill hospitalized patients worldwide. He also founded one of the first commercial decision-support software and outcomes-management companies in order to disseminate APACHE's approach to risk assessment and outcomes evaluation. In 1995 he left George Washington to start a new clinical and research department at the University of Virginia School of Medicine. By 2010, the Department of Public Health Sciences had 70 full-time faculty and staff and over $50 million in external research funding.
Dr. Knaus has received many honors during his career including an Honorary Doctor of Science Degree from Widener University and the GE Healthcare Pioneering Spirit Award.
Dr. Kathy A. Mangold is the director of the NorthShore Biospecimen Repository. Dr. Mangold received her BS cum laude in Biology in 1982 and MS in Genetics & Cell Biology in 1984, both from Washington State University in Pullman, WA, followed by her PhD in Toxicology in 1990. She is active in the Association of Molecular Pathology, particularly on the Training and Education committee and task forces.
Dr. Mangold's research has focused on the molecular biology of cancer, utilizing the molecular profile of tumors to develop non-invasive assays for early detection and/or progression to metastatic disease for epithelial neoplasms such as pancreatic and prostate cancer. Since joining NorthShore in 2000, Dr. Mangold has developed and validated rapid, real-time molecular assays for infectious, genetic and neoplastic diseases to be utilized immediately in the clinical molecular diagnostics laboratory.
Dr. Sanders has a distinguished career in research on conditions with complex genetics, with over 80 peer-reviewed genetics manuscripts. He graduated from Baylor College of Medicine, completed a general adult psychiatry residency at UCLA and postdoctoral training at NIH in psychiatric genetics. Dr. Sanders has significant experience with collaborating in large genetic studies, i.e., the “big data” approach that has proven very useful for modern genetics research, and has worked with Drs. Gejman and Duan on multiple NIH grants, including over 10 years at NorthShore together.
Dr. Sanders has particularly contributed to aspects such as large-scale sample subject recruitment and assessment, phenotypic quality control, big-data curation, phenotypic analyses, genetic epidemiology of psychiatric disorders, linkage, association, genomics, transcriptomics, cell culture and aspects central to the collection and characterization of control samples. Dr. Sanders’ work was instrumental to collect, describe and validate a large internet-based control sample that has been widely shared through NIH’s Database of Genotypes and Phenotypes (dbGaP) and accessed hundreds of times by investigators as a comparison group for the study of a wide variety of disorders and traits manifesting complex genetics. Dr. Sanders is involved with most research aspects of GHI, such as ethical issues, sample recruitment, quality control and phenotypic/clinical characterization of the collected sample.